24/7 MN – CytomX Therapeutics, Inc. (Nasdaq: CTMX) shares are trading flat this morning, after declining from it’s recent high of around $2.00

The stock is currently trading for $1.27 and has more than 4,700 trades in pre-market activity this morning. Closing in on a million shares of volume. Recent news said the phase 2 trial showed product efficacy

[mstock id=”73007″ asset=”ctmx”]

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

https://www.globenewswire.com/news-release/2022/07/06/2475436/37704/en/CytomX-Therapeutics-Announces-Phase-2-Results-for-Praluzatamab-Ravtansine-in-Breast-Cancer.html

  – Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer –

  – Secondary endpoints including clinical benefit rate at 24 weeks and median progression-free survival were 40 percent and 2.6 months, respectively –

– Arm B did not pass protocol-defined futility boundary in triple-negative breast cancer; enrollment to Arms B and C to be discontinued –

– Company to host conference call and webcast today at 5:00 pm ET / 2:00 pm PT –

SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint of confirmed objective response rate (ORR) of greater than 10 percent by central radiology review. Praluzatamab ravtansine is a DM4-conjugated, conditionally activated antibody-drug conjugate (ADC) targeting CD166 and is wholly owned by CytomX.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.